GSK price forecast: bullish setup intact? Stock remains above key moving averages

Traders Union
All News
Financial News
GSK slips 0.31% today to GBX 1,784

Highlights

GSK plc trades at GBX 1,784.00, decisively above its MA-20, MA-50, and MA-200, confirming a bullish short-, medium-, and long-term structure.
GSK's strong Q3 2025 earnings, boosted by statutory profit growth and one-offs, enabled over GBP 3 billion in shareholder returns and high R&D deal momentum.
Despite bullish technicals and ongoing buying interest, overbought oscillators and intraday resistance near GBX 1,800 suggest potential for short-term consolidation within GBX 1,752.00–GBX 1,886.50.

Shareholder payouts and deal flow boost sentiment following earnings

GSK delivered strong Q3 2025 earnings, supported by a rise in statutory profits and significant year-over-year EPS growth, aided by unusual items. The company has returned over GBP 3 billion to shareholders this year through dividends and an active share buyback program, with recent repurchases bringing its treasury holdings to above 254 million shares. Additional momentum comes from several 2025 R&D deals, including product acquisitions, a key licensing agreement with Hengrui, and an mRNA vaccine partnership with CureVac.

Resistance emerges as overbought signals temper bullish momentum

The technical outlook remains firmly bullish, as GSK is trading above all major moving averages. Key dynamic support is provided by the Ichimoku Kijun at GBX 1,656.75, while initial resistance is located near GBX 1,800, close to the recent high. Momentum indicators like MACD and ADX maintain a positive bias and support ongoing buying interest. However, multiple oscillators such as Stoch RSI, CCI, and BBP have reached overbought levels, implying some short-term exhaustion; the price currently trades within a narrow intraday range (GBX 1,782.00 to GBX 1,799.00), suggesting some near-term resistance.

Breakout potential rises as strong weekly signals drive outlook

In the next five trading days, GSK is expected to trade within a range of GBX 1,752.00 to GBX 1,886.50. Strong buy signals from RSI, MACD, and MA-50 on the weekly chart indicate a high probability (over 80%) of further price strength, with a sideways consolidation between recent support and resistance as the baseline scenario. A bullish breakout above GBX 1,800 could see a move toward the weekly high at GBX 1,886.50, while a drop below GBX 1,752.00 may lead to a pullback to the Ichimoku Kijun at GBX 1,656.75 before buyers return.

Viktoras Karapetjanc, expert at Traders Union, sees GSK's current momentum as underpinned by both robust fundamentals—such as strong Q3 2025 profits and major shareholder returns—and positive technical signals across all timeframes. He believes the combination of upbeat earnings, active R&D partnerships, and market confidence creates a solid backdrop for further price appreciation, though acknowledges near-term overbought signals may induce temporary consolidation. In his view, as long as GSK holds above key support levels, the bias remains constructive with potential for a fresh breakout. "With this kind of institutional support and technical alignment, I expect upside continuation to persist as long as the GBX 1,752.00 level is respected by buyers."

Previously it was noted that buyback activity and investor accumulation were offset by R&D pipeline risks in a period of low volatility and cautious sentiment. Technical analysis showed persistent bullish signals, with oscillators highlighting both overbought momentum and the need for caution amid mixed indicator readings.

Source of Data: GSK Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.